Effect and Safety Of Detrol LA In Men With Overactive Bladder Symptoms With Or Without Bladder Outlet Obstruction
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00147654 |
Recruitment Status :
Completed
First Posted : September 7, 2005
Last Update Posted : June 8, 2011
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Urinary Incontinence | Drug: Tolterodine ER 4 mg QD Drug: Tamsulosin 0.4 mg QD | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 830 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double |
Primary Purpose: | Treatment |
Official Title: | A Randomized, Double Blind, Placebo Controlled, Four Arm (Placebo, Tolterodine ER, Tamsulosin, and Tolterodine ER Plus Tamsulosin) Study To Evaluate The Clinical Efficacy And Safety Of Tolterodine ER 4 mg In Men Who Have Frequency and Urgency, With Or Without Urinary Urge Incontinence, With Or Without Bladder Outlet Obstruction |
Study Start Date : | November 2004 |
Actual Study Completion Date : | May 2006 |

- Patient Perception of Treatment Benefit at Week 12:
- Treatment benefit, treatment satisfaction, and willingness to continue treatment questions at week 12
- Micturition Diary- Change in number of urge incontinence episodes per 24 hours at week 1, week 6 and 12 relative to baseline.
- Change in number of urge episodes per 24 hours at week 1, week 6 and 12 relative to baseline.
- Change in number of micturitions per 24 hours at week 1, week 6 and 12 relative to baseline.
- Change in number of daytime micturitions per 24 hours at week 1, week 6 and 12 relative to baseline
- Change in number of nighttime micturitions per 24 hours at week 1, week 6 and 12 relative to baseline
- Change in the average severity of the Urinary Sensation Scale at week 1, week 6, and week 12 relative to baseline
- Change in number of OAB micturition episodes per 24 hours (OAB micturition is defined as micturition episodes associated with Urinary Sensation Scale score 3) at week 1, week 6 and week 12 relative to baseline
- Change in number of daytime OAB micturition episodes per 24 hours (OAB micturition is defined as micturition episodes associated with Urinary Sensation Scale score 3) at week 1, week 6 and week 12 relative to baseline
- Change in number of nighttime OAB micturition episodes per 24 hours. (severe OAB micturition is defined as micturition episodes associated with Urinary Sensation Scale score 4) at week 1, week 6 and week 12 relative to baseline
- Change in number of severe OAB micturition episodes per 24 hours (severe OAB micturition is defined as micturition episodes associated with Urinary Sensation Scale score 4) at week 1, week 6 and week 12 relative to baseline
- Change in number of daytime severe OAB micturition episodes per 24 hours (severe OAB micturition is defined as micturition episodes associated with Urinary Sensation Scale score 4) at week 1, week 6 and week 12 relative to baseline
- Change in number of nighttime severe OAB micturition episodes per 24 hours (severe OAB micturition is defined as micturition episodes associated with Urinary Sensation Scale score 4) at week 1, week 6 and week 12 relative to baseline
- International Prostate Symptom Score (I-PSS):
- Change in I-PSS total score at weeks 1, 6 and 12 relative to baseline
- Change in I-PSS individual item scores (Q1, Q2, Q3, Q4, Q5, Q6, and Q7) at weeks 1, 6 and 12 relative to baseline
- Change in I-PSS irritative domain (Sum of Q2, Q4, and Q7) at weeks 1, 6 and 12 relative to baseline
- Change in I-PSS obstructive domain (Sum of Q1, Q3, Q5, and Q6) at weeks 1, 6 and 12 relative to baseline
- Change in I-PSS index score (Sum Q1 to Q7) at weeks 1, 6 and 12 relative to baseline
- Change in I-PSS QoL score (Q8) at weeks 1, 6 and 12 relative to baseline
- Patient perception of urgency:
- Change in the Perception of Urgency Scale (3 point scale) at week 1, week 6 and week 12 relative to baseline
- Change in Patient's Perception of Bladder Condition at week 1, week 6 and week 12 relative to baseline
- Patient Perception of Treatment benefit at week 1 and week 6
- Treatment benefit and treatment satisfaction questions will be completed at week 1 and week 6
- Change in International Continence Society Male (ICSmaleLF) Questionnaire (long form modified) individual item scores at Week 1, Week 6 and Week 12 relative to baseline
- Change in the total score of Overactive Bladder Questionnaire (OABq) and change in total scores for each domain of OABq at week 6 and week 12 relative to baseline
- Change in the total score of International Index of Erectile Function (IIEF) and change in total scores for each domain of IIEF Questionnaire at week 6 and week 12 relative to baseline

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 40 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male 40 years of age
- Clinical signs and symptoms of frequency and urgency, with or without UUI, with or without BOO, for at least three months
- Mean urinary frequency of 8 micturitions/24h verified by the Screening micturition diary
Exclusion Criteria:
- Post-void residual urine volume (PVR) of > 200 ml as measured by an ultrasound
- Maximum urinary flow rate (Qmax) of < 5 ml/second as measured by a flowmeter; a voided volume of 75 ml is required in order to accurately record the Qmax
- Prescribed and administered an antimuscarinic or antispasmodic within 1 month
- Prescribed and administered an a-1-adrenergic antagonist within 2 weeks

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00147654

Study Director: | Pfizer CT.gov Call Center | Pfizer |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: | NCT00147654 |
Other Study ID Numbers: |
A6121120 |
First Posted: | September 7, 2005 Key Record Dates |
Last Update Posted: | June 8, 2011 |
Last Verified: | June 2011 |
Urinary Incontinence Urinary Bladder Neck Obstruction Urination Disorders Urologic Diseases Lower Urinary Tract Symptoms Urological Manifestations Urethral Obstruction Urethral Diseases Urinary Bladder Diseases Tamsulosin Tolterodine Tartrate |
Adrenergic alpha-1 Receptor Antagonists Adrenergic alpha-Antagonists Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Urological Agents Muscarinic Antagonists Cholinergic Antagonists Cholinergic Agents |